Department of Rheumatology and Immunology, Peking University People's Hospital & Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Nat Commun. 2020 Apr 20;11(1):1911. doi: 10.1038/s41467-020-15700-3.
Early diagnosis is critical to improve outcomes in rheumatoid arthritis (RA), but current diagnostic tools have limited sensitivity. Here we report a large-scale multicenter study involving training and validation cohorts of 3,262 participants. We show that serum levels of soluble scavenger receptor-A (sSR-A) are increased in patients with RA and correlate positively with clinical and immunological features of the disease. This discriminatory capacity of sSR-A is clinically valuable and complements the diagnosis for early stage and seronegative RA. sSR-A also has 15.97% prevalence in undifferentiated arthritis patients. Furthermore, administration of SR-A accelerates the onset of experimental arthritis in mice, whereas inhibition of SR-A ameliorates the disease pathogenesis. Together, these data identify sSR-A as a potential biomarker in diagnosis of RA, and targeting SR-A might be a therapeutic strategy.
早期诊断对于改善类风湿关节炎（RA）的预后至关重要，但目前的诊断工具敏感性有限。在这里，我们报告了一项涉及 3262 名参与者的培训和验证队列的大规模多中心研究。我们表明，RA 患者的血清可溶性清道夫受体-A（sSR-A）水平升高，并且与疾病的临床和免疫学特征呈正相关。sSR-A 的这种区分能力具有临床价值，可补充早期和血清阴性 RA 的诊断。sSR-A 在未分化关节炎患者中的患病率也为 15.97%。此外，SR-A 的给药可加速小鼠实验性关节炎的发病，而抑制 SR-A 则可改善疾病的发病机制。综上所述，这些数据表明 sSR-A 是 RA 诊断的潜在生物标志物，靶向 SR-A 可能是一种治疗策略。
